Drug Database
PA

pasireotide (Signifor LAR / pasireotide, LAR / pasireotide LAR)

✓ Approved

Novartis AG · SSTR1 · Small Molecule

What is pasireotide?

pasireotide is a small molecule developed by Novartis AG. It is approved for therapeutic indications via injectable (others) or intramuscular (im) injection or subcutaneous injection.

Drug Profile

Brand NamesSignifor LAR, pasireotide, LAR, pasireotide LAR
CompanyNovartis AG
Drug ClassSmall Molecule, Polypeptide
Molecular TargetSSTR1, SSTR2, SSTR3, SSTR5
RouteInjectable (Others), Intramuscular (IM) Injection, Subcutaneous Injection
StatusApproved
Sources: ClinicalTrials.gov, Novartis AG

Mechanism of Action

Molecular Targets

pasireotide acts on 4 molecular targets:

SSTR1somatostatin receptor 1 (SS-1-R, SS1-R)
SSTR2somatostatin receptor 2 (SST2)
SSTR3somatostatin receptor 3 (SST3, SS3R)
SSTR5somatostatin receptor 5 (SST5, SS-5-R)
Want deeper analysis?Noah AI can explain complex mechanisms and compare to similar drugs.

Therapeutic Indications

pasireotide is developed for 11 unique indications across 2 therapeutic areas.

Therapeutic AreaConditionPhase
Endocrine disordersAcromegaly✓ Approved
Endocrine disordersPituitary-dependent Cushing's syndrome✓ Approved
Endocrine disordersCarcinoid syndromePhase III
Neoplasms benign, malignant and unspecified (incl cysts and polyps)Colon cancer recurrentPhase III
Neoplasms benign, malignant and unspecified (incl cysts and polyps)Pituitary tumour benignPhase II

+6 more indications available with a free account

Sign up free to view all indications →

Related Research Articles

PubMedBMC surgery2026-10-15

Routine versus postoperative CRP/CT guided selective diverting ileostomy after laparoscopic low anterior resection for rectal cancer: a comparative randomized controlled trial.

Moaz Ahmed M AM, Barakat Khaled E KE, Elshazly Walid W, Zaki Yasser Y et al.

Diverting ileostomy is routinely used to protect the anastomosis after laparoscopic low anterior resection (LAR) for rectal cancer, but it exposes most patients to stoma-related morbidity even though only a minority develop a true anastomotic leak. This trial evaluated whether a postoperative C-reactive protein (CRP) and computed tomography (CT) guided selective ileostomy strategy could reduce the rate of ileostomy formation compared with routine diversion. In this RCT, 200 patients with stage II or III middle or lower third rectal cancer undergoing laparoscopic LAR were randomized 1:1 to a CRP/CT-guided selective ileostomy group (n = 100) or a routine diverting ileostomy group (n = 100). In the CRP/CT group, serum CRP was measured daily from postoperative day 1; a threshold of 114 mg/L on day 3 or a rise greater than 15 mg/L per day triggered confirmatory contrast-enhanced CT, with ileostomy formed only if findings were suspicious for leak. The primary outcome was the stoma-free status throughout the 12-month follow-up. Baseline demographic and tumor characteristics were similar between groups (all p > 0.05). Ileostomy formation was markedly lower in the CRP/CT group than the routine group (22.0% vs. 100.0%, p < 0.001). Anastomotic leak rates did not differ (0% vs. 1.0%, p = 1.000), nor did overall complication rates (31.0% vs. 32.0%, p = 0.879). Operative time (148.4 ± 14.0 vs. 166.6 ± 13.1 min, p < 0.001) and intraoperative blood loss (168.9 ± 28.2 vs. 197.3 ± 39.7 mL, p < 0.001) were significantly lower in the CRP/CT group. Stoma-related complications were far less frequent with the selective strategy (3.0% vs. 30.0%, p < 0.001). The CRP/CT group reported significantly better global health status, physical functioning, and emotional functioning scores (all p < 0.001). A postoperative CRP/CT-guided selective ileostomy strategy reduces the need for diverting ileostomy after laparoscopic low anterior resection for rectal cancer while improving operative outcomes and quality of life; however, confirmed leakage was infrequent in both groups. This approach may serve as an alternative to routine diversion in appropriately monitored surgical units. This trial was retrospectively registered at ClinicalTrials.gov (Identifier: NCT07722533) on July 17, 2026.

PMID 42875765
Read full article →
PubMedSurgical endoscopy2026-10-13

Association of the transanal approach with the accuracy of distal margin achievement in rectal cancer surgery.

Shiraishi Takuya T, Endo Mizuki M, Ozawa Naoya N, Komine Chika C et al.

Adequate distal margin (DM) achievement is essential in oncological rectal cancer surgery. In conventional transabdominal surgery, however, the intraluminal location of the distal tumor edge must be translated to an externally applied transection line; this potentially causes discrepancies between intended and achieved margins. This study aimed to evaluate the discrepancy between the planned intraoperative DM and the margin achieved in rectal cancer resection, identify factors associated with DM discrepancy, and evaluate the association between the transanal approach, specifically transanal total mesorectal excision, and DM accuracy. This retrospective cohort study included 171 consecutive patients who underwent curative-intent laparoscopic or robot-assisted low anterior resection (LAR) or intersphincteric resection between July 2019 and June 2025. The intended DM in operative records was compared with the pathological DM measured in formalin-fixed specimens. The primary outcome was the absolute DM discrepancy. As the distribution was skewed, adjusted median regression was performed using the transanal approach, intended DM, tumor distance from the anal verge, maximum tumor size, surgical platform, and surgical era as covariates. The median absolute DM discrepancy was 4.0 mm and was smaller with than without the transanal approach (3.0 vs. 6.0 mm; p < 0.001). After adjustment, transanal approach omission was associated with greater absolute DM discrepancy (β, 3.938 mm; 95% confidence interval [CI] 1.848-6.027; p < 0.001). Greater maximum tumor size was also associated with greater discrepancy (β per 1-mm increase, 0.075 mm; 95% CI 0.040-0.110; p < 0.001). This association remained consistent in sensitivity analyses restricted to LAR and after exclusion of scar-based pathological DM measurements. The transanal approach was associated with a smaller discrepancy between intended and achieved DMs after adjustment for tumor characteristics, surgical platform, and surgical era. Assessing the distal tumor edge and intended transection line within the same transanal operative field may facilitate more precise DM control.

PMID 42864471
Read full article →
PubMedSurgical endoscopy2026-10-13

Implementation of a single-port robotic platform into your colorectal surgery practice: a SAGES colorectal committee task force review of evolving robotic technology and innovations.

Sarin Ankit A, Dourado Justin J, Seffren Christopher M CM, Sidhu Upinder S US et al.

Robotic and endoscopic techniques continue to revolutionize minimally invasive surgery. Single-port (SP) robotic platforms mark a new era in minimally invasive colorectal surgery, combining single-incision/site access with full robotic articulation through a single access point. This manuscript, as a part of a four-part series, outlines specific technical considerations of the SP robotic platform including details of the platform, instrumentation, docking, and operative maneuvers. Subject matter experts from the SAGES Colorectal Committee SP Task Force performed a structured review of the currently FDA-approved SP robotic platform, assessing technical features, instrumentation, and workflow considerations for several key representative operations relevant to colorectal surgery. Three clinical areas of SP implementation included transanal robotic surgery, right colectomy, and low anterior resection (LAR). Task Force members (subject matter experts with early experience in SP robotic platforms) analyzed technical details, patient selection, and operative workflows. Representative procedural techniques were detailed with emphasis on instrumentation choice, docking strategies, and key operative steps specific to single-port colorectal surgery. The technical aspects of the SP platform include full robotic articulation through a single 25 mm port. A SP approach also enables triangulation and dexterity within confined spaces using three wristed instruments and a flexible 3-D camera. The current 360-degree boom rotation facilitates multi-quadrant manipulation without redocking. Current limitations may include continued reliance on bedside assistance for certain energy and stapling operative steps, although stapling capability has expanded with FDA clearance of an SP-compatible 45 mm stapler as of April 2025. Training of the entire operative team and gradual progression of case complexity is recommended as the surgeon implements this new technology into clinical practice. A SP robotic approach to minimally invasive colorectal surgical procedures is feasible for a range of colorectal surgery operations. In select procedures like SP TAMIS, SP right colectomy, and SP-LAR, the single-port platform appears to offer advantages related to reduced invasiveness and improved surgeon ergonomics compared to other minimally invasive approaches. Successful implementation requires structured training, careful patient selection, and adherence to evidence-based adoption principles.

PMID 42864467
Read full article →
PubMedThe journal of obstetrics and gynaecology research2026-10-09

BUN/Albumin Ratio in Preeclampsia: A Comparative Study of Seven Biomarker Ratios.

Bademler Neslihan N, Sayan Sena S, Çaltek Hale Özer HÖ, Güler Emine Yılmaz EY et al.

To evaluate whether the admission blood urea nitrogen to albumin ratio (BAR) predicts adverse maternal and perinatal outcomes in preeclampsia, and to compare its performance against six other laboratory-derived ratios. Records of 252 preeclamptic pregnancies were reviewed and dichotomised at a BAR cut-off of 3.0: low (< 3.0, n = 135) and high (≥ 3.0, n = 117). Composite adverse maternal outcomes included severe complication, intensive-care admission, or transfusion; composite adverse perinatal outcomes included growth restriction, stillbirth, neonatal death, neonatal-unit admission, or 5-min Apgar below 7. BAR was benchmarked against six other ratios: uric acid/albumin ratio (UAR), lactate dehydrogenase/albumin ratio (LAR), C-reactive protein/albumin ratio (CAR), fibrinogen/CRP ratio, fibrinogen/albumin ratio (FAR), and aspartate aminotransferase/alanine aminotransferase (AST/ALT) ratio (De Ritis) by ROC analysis. Independent predictors were sought through multivariable logistic regression. Patients in the high-BAR stratum showed substantially higher rates of composite adverse obstetric outcome (78.6% vs. 54.1%; p < 0.001), composite adverse maternal outcome (28.2% vs. 6.7%; p < 0.001), maternal intensive-care admission (16.2% vs. 3.7%; p = 0.001), and transfusion (12.0% vs. 2.2%; p = 0.002). BAR yielded the most balanced discrimination across endpoints, with AUCs of 0.68 (95% CI: 0.61-0.75) for the obstetric composite, 0.74 (95% CI: 0.65-0.83) for the maternal composite, and 0.66 (95% CI: 0.59-0.73) for the perinatal composite (all p < 0.01); fibrinogen/albumin and AST/ALT ratios were not predictive. BAR did not differ significantly from UAR or LAR by DeLong test (all p > 0.05) and retained independent association with adverse perinatal outcome after adjustment (adjusted OR 1.32; 95% CI: 1.03-1.70; p = 0.03). Sensitivity analyses showed that UAR retained independent significance for all three composite endpoints, positioning BAR and UAR as complementary bedside markers. An elevated admission BAR identifies preeclamptic women at higher risk of severe maternal and perinatal events, with performance comparable to that of UAR. Both BAR and UAR may serve as simple complementary bedside adjuncts to existing risk stratification tools in preeclampsia.

PMID 42853129
Read full article →
PubMedAdvanced materials (Deerfield Beach, Fla.)2026-10-07

CRISPR Nanomachinery-Sensitized Nanocatalytic Tumor Ferroptosis in Triple-Negative Breast Cancer.

Wang Yuemei Y, Liang Leilei L, Huo Dongliang D, Ge Dejie D et al.

The luminal androgen receptor (LAR) subtype of triple-negative breast cancer (TNBC) represents a formidable therapeutic challenge, necessitating sophisticated strategies that exploit unique tumor vulnerabilities. In the present work, we introduce a biomimetic nanotherapeutic that integrates single-atom iron nanocatalysts (FeSA) co-loaded with a CRISPR-Cas9 plasmid targeting Glutathione Peroxidase 4 (Gpx4), the key regulator of ferroptosis, and is camouflaged with a homologous cancer cell membrane to ensure precise tumor tropism and excellent biocompatibility. In an orthotopic LAR-TNBC model, the nanotherapeutic achieved ∼98% tumor regression and markedly extended survival. Comprehensive mechanistic analyses confirmed efficient on-target Gpx4 disruption, which synergistically amplified the FeSA-catalyzed ferroptotic cascade. Unbiased transcriptomic profiling further revealed extensive reprogramming of the tumor molecular landscape, resulting in significant cancer cell ferroptosis by DNA damage response and p53 signaling pathway activation. This work establishes a highly synergistic and targeted approach, presenting a potent therapeutic modality for aggressive and chemoresistant malignancies.

PMID 42839688
Read full article →
PubMedFrontiers in nephrology2026-10-06

The lactate dehydrogenase-to-albumin ratio is independently associated with moderate-to-severe tubulointerstitial fibrosis in patients with IgA nephropathy.

Zheng Luli L, Yang Guokai G

Tubulointerstitial fibrosis accelerates the progression of immunoglobulin A nephropathy (IgAN) to end-stage renal disease (ESRD). While renal biopsy is the standard for evaluation, non-invasive biomarkers remain scarce. This study investigated the independent association and diagnostic value of the lactate dehydrogenase-to-albumin ratio (LAR) for moderate-to-severe tubulointerstitial fibrosis (Oxford T1+T2) in IgAN patients. We retrospectively analyzed 398 patients with biopsy-proven primary IgAN, categorized into no/mild fibrosis (T0, n=273) and moderate-to-severe fibrosis (T1+T2, n=125) groups. Clinical, laboratory, and pathological data were collected to calculate LAR. Missing data were handled using multiple imputation by chained equations (MICE). Statistical evaluations included logistic regression, ROC curves, restricted cubic splines (RCS), and subgroup analyses. The T1+T2 group exhibited significantly higher median LAR levels (5.10 vs. 4.13, P < 0.001). Following adjustment for confounders, LAR remained independently associated with fibrosis (OR = 1.425, 95% CI: 1.122-1.809, P = 0.004). The AUC was 0.717, with an optimal cut-off of 4.91 (sensitivity 56.8%, specificity 78.0%). RCS analysis indicated a linear relationship (P for non-linearity = 0.2350). Subgroup analyses showed consistent positive associations (OR > 1.2), reaching statistical significance in males, patients aged ≥40 years, and those with eGFR ≥60 mL/min/1.73 m². Sensitivity analyses confirmed robustness. Patients with LAR > 4.91 demonstrated worse renal function, heavier proteinuria, and higher fibrosis incidence (54.2% vs. 20.2%, P < 0.001). LAR is independently associated with moderate-to-severe tubulointerstitial fibrosis and demonstrates moderate diagnostic efficacy. As a cost-effective indicator, LAR may serve as a non-invasive auxiliary tool for clinical screening and risk stratification in IgAN, but it cannot replace renal biopsy as the diagnostic gold standard.

PMID 42835361
Read full article →

+5325 more articles available with a free account

Sign up free to view all articles →

Ask about pasireotide